<- Go Home
Akouos, Inc.
Akouos, Inc. develops gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A, and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts. Akouos, Inc. operates as a subsidiary of Eli Lilly and Company.
Market Cap
$491.0M
Volume
193.0K
Cash and Equivalents
$75.4M
EBITDA
-$90.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$13.60
52 Week Low
$2.31
Dividend
N/A
Price / Book Value
2.71
Price / Earnings
-5.09
Price / Tangible Book Value
2.71
Enterprise Value
$357.1M
Enterprise Value / EBITDA
-4.19
Operating Income
-$93.2M
Return on Equity
42.37%
Return on Assets
-22.28
Cash and Short Term Investments
$169.3M
Debt
$35.4M
Equity
$180.8M
Revenue
N/A
Unlevered FCF
-$59.8M
Sector
Biotechnology
Category
N/A